Clinical Trials
48 trialsTesting the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Institutes of Health Clinical Center (CC)
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
National Cancer Institute (NCI)
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
National Cancer Institute (NCI)
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
National Cancer Institute (NCI)
CC-5013 in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas
National Cancer Institute (NCI)
Radiation Therapy in Treating Patients With Glioblastoma
National Cancer Institute (NCI)
Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
National Cancer Institute (NCI)
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
National Cancer Institute (NCI)
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
National Cancer Institute (NCI)
IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma
National Cancer Institute (NCI)
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
National Cancer Institute (NCI)
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
National Cancer Institute (NCI)
Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas
National Cancer Institute (NCI)
Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma
National Cancer Institute (NCI)
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
National Cancer Institute (NCI)
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
National Cancer Institute (NCI)
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
RO4929097 in Treating Patients With Recurrent Invasive Gliomas
National Cancer Institute (NCI)
Bortezomib in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
National Cancer Institute (NCI)
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
National Institutes of Health Clinical Center (CC)
Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Carmustine in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors
National Cancer Institute (NCI)
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain
National Cancer Institute (NCI)
Brachytherapy in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas
National Cancer Institute (NCI)
Karenitecin in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)